Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 17/20 | 0.70 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30146928 | 1.00 | ENPP2 (0.70) | ENPP2JAK2JAK1JAK3LMNA | |
| SCHEMBL16739433 | 0.94 | ENPP2 (0.81) | ENPP2ABCB1 | |
| SCHEMBL30146891 | 0.94 | ENPP2 (0.81) | ENPP2ABCB1 | |
| SCHEMBL671024 | 0.93 | ENPP2 (0.70) | ENPP2JAK2JAK1JAK3LMNA | |
| SCHEMBL16739511 | 0.93 | ENPP2 (0.63) | ENPP2JAK2JAK1JAK3LMNA | |
| SCHEMBL30146968 | 0.93 | ENPP2 (0.63) | ENPP2JAK2JAK1JAK3LMNA | |
| SCHEMBL16739495 | 0.90 | ENPP2 (0.61) | ENPP2JAK2JAK1JAK3LMNA | |
| SCHEMBL30146963 | 0.90 | ENPP2 (0.61) | ENPP2JAK2JAK1JAK3LMNA | |
| SCHEMBL16739404 | 0.89 | ENPP2 (0.82) | ENPP2JAK2JAK1JAK3LMNA | |
| SCHEMBL30146952 | 0.89 | ENPP2 (0.82) | ENPP2JAK2JAK1JAK3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110372671-B | Autotaxin inhibitor compounds | 赛博治疗有限责任公司 | 2023-02-21 | — | — | CN | claimed |
| US-20220265608-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | DF 2024 IP ACQUISITION, LLC | 2022-08-25 | — | — | US | claimed |
| US-11344533-B2 | Autotaxin inhibitor compounds | SABRE THERAPEUTICS LLC (US) | 2022-05-31 | — | — | US | claimed |
| EP-3878848-A1 | AUTOTAXIN INHIBITING INDOLE COMPOUNDS | Sabre Therapeutics LLC (US) | 2021-09-15 | — | — | EP | claimed |
| US-12458627-B2 | Autotaxin inhibitors and uses thereof | DF 2024 IP ACQUISITION, LLC (US) | 2025-11-04 | — | — | US | disclosed |
| US-11779568-B2 | Autotaxin inhibitor compounds | SABRE THERAPEUTICS LLC (US) | 2023-10-10 | — | — | US | disclosed |
| CN-110372671-B | Autotaxin inhibitor compounds | 赛博治疗有限责任公司 | 2023-02-21 | — | — | CN | disclosed |
| US-20220265608-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | DF 2024 IP ACQUISITION, LLC | 2022-08-25 | — | — | US | disclosed |
| EP-4026549-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | Sabre Therapeutics LLC (US) | 2022-07-13 | — | — | EP | disclosed |
| EP-4026549-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | Sabre Therapeutics LLC (US) | 2022-07-13 | — | — | EP | disclosed |
| US-11344533-B2 | Autotaxin inhibitor compounds | SABRE THERAPEUTICS LLC (US) | 2022-05-31 | — | — | US | disclosed |
| EP-3302490-B1 | AUTOTAXIN INHIBITORS AND USES THEREOF | SABRE THERAPEUTICS LLC (US) | 2022-04-13 | — | — | EP | disclosed |
| US-20160374991-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | DF 2024 IP ACQUISITION, LLC | 2016-12-29 | — | — | US | disclosed |
| WO-2016191427-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | PHARMAKEA, INC. (US) | 2016-12-01 | — | — | WO | disclosed |
| US-9468628-B2 | Autotaxin inhibitor compounds | PHARMAKEA, INC (US) | 2016-10-18 | — | — | US | disclosed |
| EP-3071561-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | Pharmakea Inc. (US) | 2016-09-28 | — | — | EP | disclosed |
| US-20160235713-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | DF 2024 IP ACQUISITION, LLC | 2016-08-18 | — | — | US | disclosed |
| US-9334261-B2 | Autotaxin inhibitor compounds | PHARMAKEA, INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-20160046614-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | DF 2024 IP ACQUISITION, LLC | 2016-02-18 | — | — | US | disclosed |
| WO-2015077503-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | PHARMAKEA, INC. (US) | 2015-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160374991-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | ENPP2, SERPINB1, SERPINE1 | ENPP2 1/4885JAK2 3983/4885JAK1 4431/4885 |
| US-11779568-B2 | Autotaxin inhibitor compounds | ENPP2, SERPINB1, SERPINE1 | ENPP2 1/4885JAK2 3983/4885JAK1 4431/4885 |
| US-12458627-B2 | Autotaxin inhibitors and uses thereof | ENPP2, SERPINB1, RNASE1 | ENPP2 1/4885JAK2 4030/4885JAK1 4276/4885 |
| US-20160046614-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | ENPP2, SERPINB1, SERPINE1 | ENPP2 1/4885JAK2 3983/4885JAK1 4431/4885 |
| US-11344533-B2 | Autotaxin inhibitor compounds | ENPP2, SERPINB1, SERPINE1 | ENPP2 1/4885JAK2 3983/4885JAK1 4431/4885 |
| US-20220265608-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | ENPP2, SERPINB1, SERPINE1 | ENPP2 1/4885JAK2 3983/4885JAK1 4431/4885 |
| US-20160235713-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | ENPP2, SERPINB1, SERPINE1 | ENPP2 1/4885JAK2 3983/4885JAK1 4431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.